Digitalis in heart failure! Still applicable?

U C Hoppe1, E Erdmann

  • 1Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. uta.hoppe@uni-koeln.de

Zeitschrift Fur Kardiologie
|May 4, 2005
PubMed

Insights

Cardiac glycosides, like digitalis, can help heart failure patients with sinus rhythm. Low serum concentrations are key for benefits, with no sex-based differences in effectiveness, making them a viable option regardless of gender.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac glycosides are used for heart failure with atrial fibrillation to control ventricular rate.
  • The use of digitalis in systolic heart failure with sinus rhythm remains debated, with concerns about increased mortality in women.

Purpose of the Study:

  • To evaluate the effectiveness and safety of cardiac glycosides in patients with heart failure and sinus rhythm.
  • To investigate potential sex-based differences in cardiac glycoside effectiveness.
  • To determine optimal serum digoxin concentrations for therapeutic benefit.

Main Methods:

  • Retrospective analysis of patient data.
  • Examination of cardiac glycoside effectiveness and mortality rates.
  • Assessment of serum digoxin concentrations and their correlation with outcomes.

Main Results:

  • Retrospective analyses show no sex-based differences in cardiac glycoside effectiveness.
  • Beneficial effects are linked to low serum digoxin concentrations (0.5-0.8 ng/ml), associated with attenuated sympathetic activation.
  • High serum levels correlate with increased mortality.

Conclusions:

  • Cardiac glycosides should be considered for symptomatic heart failure patients with sinus rhythm, even with optimal ACE inhibitor, beta-blocker, and diuretic therapy.
  • Therapy should aim for low target serum digoxin concentrations (0.5-0.8 ng/ml) irrespective of patient gender.
  • Digitalis offers benefits through neurohumoral modulation at therapeutic concentrations.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...